U.S. Commercial Services Stock News

Hims & Hers Health launched a compounded oral semaglutide pill as a low cost alternative to a major weight loss drug. Novo Nordisk responded by accusing the company of illegal mass compounding and threatened legal and regulatory action. The dispute centers on patient safety, intellectual property, and how compounded GLP 1 weight loss drugs are marketed and sold. Hims & Hers Health (NYSE:HIMS), trading at $24.4, is moving aggressively into the weight loss drug category, a high profile area...

If you are wondering whether Corpay at around US$300.28 is starting to look interesting, this article will help you connect the current share price to what the business may be worth. The stock has seen a 5.5% decline over the last 7 days, a 2.7% decline over the last 30 days, is roughly flat year to date at 0.1% decline, and is 22.7% lower over the last year. The 3 year and 5 year returns sit at 43.7% and 14.6% respectively. Recent news around Corpay has largely focused on ongoing investor...

If you are wondering whether CRISPR Therapeutics at around US$50.17 offers fair value or a potential mispricing, you are not alone. The stock has recently been choppy, with a 7 day return of 6.6% decline, a 30 day return of 9.0% decline, and a year to date move of 6.7% decline, although the 1 year return stands at 18.8% while the 3 year and 5 year returns are 6.0% decline and 68.7% decline respectively. Recent attention on gene editing and CRISPR based therapies has kept the company in the...

In recent days, Endava reiterated its emphasis on complex digital transformation projects while issuing conservative guidance that reflects slower revenue growth and cautious enterprise demand. This shift in tone has prompted a more reserved stance from analysts, who are reassessing the company’s risk profile and longer-term growth narrative. With conservative guidance underscoring slower revenue growth, we’ll now examine how this development reshapes Endava’s broader investment narrative...

Earnings and dividend announcement set the tone NBT Bancorp (NBTB) has just reported fourth quarter and full year 2025 results in line with Wall Street expectations, along with a higher quarterly dividend and updates on loan charge offs and share repurchases. See our latest analysis for NBT Bancorp. The earnings beat in 2025, higher dividend and ongoing share repurchases come as the stock has built positive momentum, with a 90 day share price return of 12.75% and a 5 year total shareholder...

Amphenol (NYSE:APH) has announced that President and CEO R. Adam Norwitt will be appointed Chairman of the Board at the 2026 Annual Meeting. The move follows the planned retirement of long serving Chairman Martin H. Loeffler, who has been a central figure in shaping the company’s direction. The leadership transition brings the CEO and Chair roles under a single executive, marking a key shift in Amphenol’s governance structure. For investors watching Amphenol at a share price of $130.0, this...

If you are wondering whether Symbotic at around US$53.48 is offering good value or asking too much, you are not alone. The stock has seen a 22.1% decline over the last 30 days and is down 17.6% year to date, even though the 1 year return sits at 73% and the 3 year return is 195.3%. Recent headlines have focused on Symbotic's role in warehouse automation and its partnerships with major retailers. This helps explain why expectations around its long term growth story remain a key talking point...

Clearwater Analytics Holdings (NYSE:CWAN) has integrated its platform with TreasurySpring, giving institutional clients access to over 1,000 fixed term cash investment products. The company also introduced embedded AI features in its Beacon risk platform to support real time model validation, scenario analysis, and operational automation. Clearwater Analytics Holdings is trading at $23.46, with the share price showing a 20.2% return over the past 3 years and an 18.2% decline over the past...

Over the past year, Sunstone Hotel Investors has benefited from a recovering lodging market, steady dividend growth, and active portfolio reshaping through asset sales and selective acquisitions in high barrier to entry locations. Management’s emphasis on ongoing renovations and asset repositioning to enhance competitive strength, supported by stable business and leisure travel demand, is increasingly central to the company’s long-term investment story. We’ll now examine how Sunstone Hotel...

Freeport-McMoRan (FCX) is back in the spotlight after its fourth quarter and full year 2025 earnings, where management reaffirmed production guidance, highlighted cash flow discipline, and emphasized flexibility around growth projects and shareholder returns. See our latest analysis for Freeport-McMoRan. The earnings update comes after a sharp run in Freeport-McMoRan’s share price, with a 90 day share price return of 60.05% and a 1 year total shareholder return of 70.99%. However, the latest...

Nu Holdings (NYSE:NU) has received conditional approval to establish a de novo US national bank, Nubank, N.A. US regulators granted the conditional approval as part of Nu's effort to expand its presence in the US market. Roberto Campos Neto, former President of Brazil's Central Bank, has been appointed Chairman of Nubank, N.A. Co founder Cristina Junqueira is relocating to lead Nu's US operations, signaling a stronger focus on North American growth. Nu Holdings, trading at $17.02, has seen...

Hilton Worldwide Holdings (NYSE:HLT) is facing continued weakness in revenue per available room, adding pressure to its core hotel operations. The company is expected to see shrinking free cash flow margins, raising questions about how comfortably it can sustain profitability. These operational headwinds come at a time when technical chart signals for NYSE:HLT appear positive, creating a split picture for investors. Hilton Worldwide Holdings, trading at $308.81, sits at the center of a...

If you are trying to figure out whether Coinbase Global's share price makes sense right now, you are not alone. This article is built to help you weigh up what you are really paying for. The stock recently closed at US$168.62, after a 15.3% decline over the last 7 days, a 32.7% decline over 30 days, a 28.7% decline year to date, and a 37.6% decline over the past year. The 3 year return sits at a very large 182.8%. Recent headlines around Coinbase have focused on the broader crypto sector,...

Tempus AI recently reported clinical validation results showing that its Immune Profile Score (IPS) test more accurately predicts outcomes for patients receiving immune checkpoint inhibitors than conventional biomarkers like tumor mutational burden, microsatellite instability, and PD-L1, while also confirming record contract value of over US$1.10 billions and expanding its AI pathology offerings. An interesting insight is that IPS identified subgroups of microsatellite-stable colorectal and...

Griffon’s quarter, guidance, and new joint venture Griffon (GFF) stock is in focus after the company reported first quarter results, issued 2026 revenue guidance of US$1.8b, announced a new global tools joint venture with ONCAP, and affirmed its regular cash dividend. See our latest analysis for Griffon. Griffon’s recent earnings release, 2026 revenue guidance of US$1.8b, and the new ONCAP joint venture have coincided with building momentum, with a 30 day share price return of 13.23% and a 5...

In late January 2026, Joby Aviation raised roughly US$1.20 billion through a completed US$600 million follow-on common stock offering and US$600 million of 0.75% senior subordinated unsecured convertible notes due February 15, 2032. This mix of equity and long-dated convertible debt materially boosts Joby’s funding for eVTOL certification and production while increasing dilution and capital structure complexity for shareholders. Against this backdrop, we’ll examine how Joby’s large blended...

AXT (NasdaqGS:AXTI) is supplying Indium Phosphide substrate wafers for AI driven data center build outs as demand for advanced optical and high speed connectivity rises. The company is leveraging its established sourcing and pricing approach in a sector that combines high growth potential with elevated operational and geopolitical risks. AXT recently updated its board structure, with Leonard J. LeBlanc now classified as an independent director and appointed Chair of the Audit...

AbCellera Biologics recently highlighted its transition from a service-focused antibody discovery platform to a clinical-stage biotech, with proprietary candidates ABCL635 and ABCL575 now in Phase 1 trials and more than 100 partnered programs contributing potential royalties. This shift toward owning drug assets, alongside a broad royalty portfolio that includes 18 clinical programs, marks a meaningful change in how AbCellera may create and capture value within biopharma. We’ll now examine...

Recent performance snapshot for Astec Industries (ASTE) Astec Industries (ASTE) has drawn fresh attention after a strong run over the past year, with the stock showing positive returns over the past month, past 3 months, and year to date. See our latest analysis for Astec Industries. The recent 7 day share price return of 14.29% and 30 day share price return of 17.73% build on a year to date share price return of 22.03%, while the 1 year total shareholder return of 63.86% contrasts with a...

Avis Budget Group has already begun consolidating its Zipcar subsidiary’s corporate operations by closing Zipcar’s Boston headquarters, cutting more than 100 roles, and shifting oversight to the parent’s New Jersey base while keeping local field and fleet teams in place to maintain service in existing markets. This move underscores Avis Budget Group’s effort to tighten costs around Zipcar, treating car-sharing as a more experimental part of its portfolio while centralizing resources for...

Fresh guidance gives investors clearer guardrails Life Time Group Holdings (LTH) recently issued earnings guidance for the fourth quarter of 2025 and the full years 2025 and 2026, giving investors fresh revenue and profit ranges to anchor expectations. The company outlined projected Q4 2025 revenue of about $743 million to $745 million, with net income of $120 million to $123 million, alongside updated full year views that extend into 2026. See our latest analysis for Life Time Group...

USA Rare Earth (NasdaqGM:USAR) has secured a non binding commitment for $1.6b in U.S. government loans and grants tied to its mine and magnet projects. The company has also raised $1.5b from private investors as part of a broader funding package. USA Rare Earth is participating in the new $12b federally backed Project Vault rare earth stockpile program. Government involvement includes equity participation and a trading bloc structure with price floors for participating suppliers. USA Rare...

If you are looking at Praxis Precision Medicines and wondering whether the recent excitement is already in the price, you are not alone. The stock closed at US$303.34, with a 9.5% gain over the last 30 days, a 5.9% return year to date, a 243.8% return over 1 year, a 366.0% return over 3 years, and a 62.0% decline over 5 years. Recent company specific news has kept Praxis in focus for investors and added context to these share price moves. Headlines around its pipeline progress, regulatory...

Caesars Entertainment (CZR) is back in focus after launching Phase Two of its US$200 million overhaul of Caesars Republic Lake Tahoe, adding upgraded pool facilities, expanded meeting space and new Clique Hospitality backed dining and entertainment. See our latest analysis for Caesars Entertainment. The Phase Two announcement has arrived alongside a 6.76% 1 day share price return and a 14.56% 90 day share price return. However, the 1 year total shareholder return of 39.55% and 5 year total...